Press Releases
 2011
PRESS RELEASE | Warsaw, 12 October 2011
Meeting today in Warsaw, the European Generic medicines Association’s Board announced the election of Gudbjorg Edda Eggertsdottir as its new President. Ms Eggertsdottir has been active in the generic medicines industry for over 30 years, witnessing the many challenges it has already faced on its way to becoming an essential part of the global healthcare offering. She has an impressive industry pedigree, which includes significant experience in the generic medicines sector in companies such as Actavis – where she is currently President Iceland, Strategic Projects – and Delta. Ms Eggertsdottir has been part of the EGA Executive Board for two years. More...
PRESS RELEASE | Brussels, 11 October 2011
The European Generic medicines Association (EGA) welcomes the revised proposals on information to patients published today by the European Commission. The EGA sees this move as a constructive step forward as the proposals ensure a proper balance between improving access to information available from companies and preventing the exertion of undue commercial influence on patients, as advocated by MEPs in the proposition’s first reading. The proposals also emphasise the use of quality criteria for information to patients and the role of competent authorities in verifying and monitoring the information. More...
PRESS RELEASE | Brussels, 22 June 2011
The European Generic medicines Association (EGA) officially launched the code of conduct on slot booking for Marketing Authorisation Applications (MAA) as the generic medicines industry’s contribution to the process of improving the functioning of the EU regulatory system. More...
PRESS RELEASE | Cascais, 17 June 2011
Europe must seize on new opportunities to increase employment and create growth in the generic and biosimilar medicines markets. This was a key message delivered at the 17th Annual Conference of the European Generic medicines Association in Lisbon on 16-17 June 2011. More...
PRESS RELEASE | 14 April 2011
“There is a need for an EU industrial policy for the biosimilar medicines industry. The EGA will therefore continue to be at the forefront of the biosimilars debate working with EU and global policy makers” said Didier Barret, EGA President, in his opening address to the 9th EGA International Symposium on Biosimilar Medicines today in London. The EGA President welcomed the EU biosimilars’ framework which is operational and delivering, he also reminded the audience that biosimilar medicines have been safely in use for 5 years. More...
PRESS RELEASE | 16 February 2011
The European Generic medicines Association (EGA) welcomes today’s vote by Members of the European Parliament which seeks greater protection for EU patients by preventing the proliferation of falsified medicinal products in the EU. More...
PRESS RELEASE | 25 January 2011
"The EU regulatory environment needs to be optimised in order to deal with the growing demand for generic and biosimilar medicines. These medicines, which are now front-line treatments for a whole range of chronic diseases and account for nearly 50% of all medicines dispensed to European patients are the key to healthcare sustainability in the EU and the European regulatory system needs to reflect this reality." This was the key message of Greg Perry, Director General of the European Generic medicines Association (EGA), as he presented the association’s Vision 2015 at the EGA’s 10th Regulatory and Scientific Affairs Conference, held in London today. More...
|
